INBIOGEN Co., Ltd. (KRX:101140)

INBIOGEN Statistics

Total Valuation

INBIOGEN has a market cap or net worth of KRW 75.19 billion. The enterprise value is 75.76 billion.

Market Cap	75.19B
Enterprise Value	75.76B

Important Dates

The last earnings date was Wednesday, May 27, 2026.

Earnings Date	May 27, 2026
Ex-Dividend Date	n/a

Share Statistics

INBIOGEN has 9.98 million shares outstanding.

Current Share Class	9.98M
Shares Outstanding	9.98M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	n/a
Float	2.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.81
PB Ratio	0.53
P/TBV Ratio	0.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.18
EV / Sales	13.92
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-17.61

Financial Position

The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.03.

Current Ratio	1.57
Quick Ratio	1.56
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.95
Interest Coverage	-37.88

Financial Efficiency

Return on equity (ROE) is -11.90% and return on invested capital (ROIC) is -2.65%.

Return on Equity (ROE)	-11.90%
Return on Assets (ROA)	-1.60%
Return on Invested Capital (ROIC)	-2.65%
Return on Capital Employed (ROCE)	-2.78%
Weighted Average Cost of Capital (WACC)	7.46%
Revenue Per Employee	132.77M
Profits Per Employee	-442.15M
Employee Count	41
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.02% in the last 52 weeks. The beta is 0.64, so INBIOGEN's price volatility has been lower than the market average.

Beta (5Y)	0.64
52-Week Price Change	-38.02%
50-Day Moving Average	8,216.20
200-Day Moving Average	10,710.25
Relative Strength Index (RSI)	50.72
Average Volume (20 Days)	30,358

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, INBIOGEN had revenue of KRW 5.44 billion and -18.13 billion in losses.

Revenue	5.44B
Gross Profit	-516.42M
Operating Income	-3.99B
Pretax Income	-18.13B
Net Income	-18.13B
EBITDA	-3.75B
EBIT	-3.99B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 3.53 billion in cash and 4.11 billion in debt, with a net cash position of -575.79 million or -57.67 per share.

Cash & Cash Equivalents	3.53B
Total Debt	4.11B
Net Cash	-575.79M
Net Cash Per Share	-57.67
Equity (Book Value)	142.98B
Book Value Per Share	n/a
Working Capital	2.81B

Cash Flow

In the last 12 months, operating cash flow was -4.29 billion and capital expenditures -10.10 million, giving a free cash flow of -4.30 billion.

Operating Cash Flow	-4.29B
Capital Expenditures	-10.10M
Depreciation & Amortization	241.84M
Net Borrowing	3.29B
Free Cash Flow	-4.30B
FCF Per Share	-430.99

Margins

Gross Margin	-9.49%
Operating Margin	-73.31%
Pretax Margin	-333.01%
Profit Margin	n/a
EBITDA Margin	-68.86%
EBIT Margin	-73.31%
FCF Margin	n/a

Dividends & Yields

INBIOGEN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-24.11%
FCF Yield	-5.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 21, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Sep 21, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

INBIOGEN has an Altman Z-Score of 12.49 and a Piotroski F-Score of 1.

Altman Z-Score	12.49
Piotroski F-Score	1